Lundbeck Signals New Hope for Parkinson's with Promising Oral Drug Data

COPENHAGEN, Denmark – March 16, 2026 – Danish biopharmaceutical company H. Lundbeck A/S has unveiled promising early-stage clinical data for a new oral treatment for advanced Parkinson's disease, setting the stage for a significant presence at the upcoming 2026 Alzheimer's and Parkinson's Disease (AD/PD™) conference.

The company announced that data from a Phase 1b trial of its investigational compound, Lu AF28996, demonstrated a favorable safety profile and early signs of clinical efficacy. This news offers a potential new avenue for patients grappling with the debilitating motor fluctuations that characterize the later stages of the disease. The announcement is part of a larger showcase of five presentations at the prestigious conference, highlighting the company's dual-front strategy against complex movement disorders, including a concerted effort to develop a treatment for the rare and fatal Multiple System Atrophy (MSA).

Addressing a Critical Gap in Parkinson's Care

For many individuals living with advanced Parkinson's disease, daily life is a battle against the condition's unpredictable nature. Despite existing therapies, patients frequently experience debilitating motor fluctuations, including periods of severe stiffness and immobility known as "OFF" time, which can unpredictably alternate with periods of uncontrolled, involuntary movements called dyskinesia. While current treatments like levodopa remain a cornerstone of therapy, their long-term use can contribute to these very complications. More advanced, device-aided therapies, such as infusion pumps or deep brain stimulation, can be effective but come with significant practical limitations and surgical risks, making them unsuitable or undesirable for many.

Lundbeck's Lu AF28996 aims to address this specific treatment gap. As a novel, orally administered D1/D2 receptor agonist, it is designed to provide continuous stimulation to the brain's dopamine receptors, mimicking the action of the neurotransmitter that is lost in Parkinson's. The goal is to smooth out the peaks and troughs associated with standard levodopa therapy, thereby reducing both "OFF" time and dyskinesia. The convenience of an oral pill represents a significant potential improvement in quality of life over more invasive methods.

The Phase 1b trial results, to be presented in detail by Dr. Alberto Cucca at the AD/PD™ conference, evaluated the compound in patients with advanced Parkinson's. According to Lundbeck, the drug was generally well tolerated and showed early clinical signals consistent with its intended mechanism. These positive findings have provided the company with the confidence to move forward.

"Phase 1b patient trials are an important step in understanding the safety profile and biological activity of new investigational therapies in early clinical development," said Johan Luthman, EVP and Head of Research & Development at Lundbeck. "These data provide supportive evidence to further evaluate the potential of Lu AF28996 in the treatment of people with advanced Parkinson's disease." Based on this evidence, Lundbeck will initiate a larger Phase 2 study in 2026.

A Deeper Commitment: Tackling the Enigma of MSA

Beyond Parkinson's, Lundbeck is also directing its scientific firepower at Multiple System Atrophy (MSA), a far rarer but even more aggressive neurodegenerative disorder. MSA progresses rapidly, causing severe autonomic dysfunction, parkinsonism, and cerebellar ataxia, and is ultimately fatal, typically within nine years of onset. Crucially, there are currently no approved treatments that can slow or halt its relentless progression.

At the AD/PD™ conference, Lundbeck will showcase a broad research program that underpins its development of amlenetug, an investigational antibody for MSA. Amlenetug targets alpha-synuclein, the misfolded protein believed to be a key driver of the disease's pathology. By binding to and clearing this protein, the therapy is intended to stop the chain reaction of cellular damage that leads to neurodegeneration. This approach has garnered both Orphan Drug Designation and FDA Fast Track Designation, acknowledging the profound unmet need in MSA.

Lundbeck's conference presentations reveal a strategy that goes far beyond a single molecule. The company will share insights on using advanced Bayesian statistical models to better interpret clinical trial results, progress in developing biomarkers to enable earlier and more accurate diagnosis, and the critical importance of integrating the patient's voice directly into trial design. These foundational efforts are essential for increasing the chances of success in a field where many previous investigational therapies have failed, often due to the complexities of diagnosing and tracking the disease. This comprehensive approach has directly informed the design of the ongoing pivotal Phase 3 trial for amlenetug.

A Strategic Focus on Neuroscience's Toughest Challenges

The dual announcements on Parkinson's and MSA are not isolated events but rather a clear demonstration of Lundbeck's overarching "Focused Innovator Strategy." As a company that has dedicated itself exclusively to brain health for over 70 years, its modern R&D pipeline is aimed squarely at the most challenging and underserved areas of neurology and psychiatry. The breadth of its work, from the relatively common (Parkinson's) to the neuro-rare (MSA), highlights a deep commitment to its specialization.

This focus is backed by significant financial investment. The company has stated its intention to steadily increase its R&D spending to a target of 20-25% of revenue, a substantial commitment that signals its belief in the long-term value of its innovation pipeline. By presenting a robust and diverse portfolio of research at a major international conference, Lundbeck reinforces its position as a key player in the neuroscience landscape, signaling to patients, physicians, and investors that it is dedicated to tackling the underlying biology of these complex diseases.

While both Lu AF28996 and amlenetug remain investigational compounds years away from potential regulatory approval, the progress represents a tangible step forward. The path to developing new drugs for neurodegenerative conditions is fraught with high rates of failure. Success requires not only innovative science but also a deep understanding of disease progression, robust clinical trial design, and an unwavering commitment to patient needs. Lundbeck's comprehensive strategy in movement disorders demonstrates an understanding that scientific breakthroughs are built upon a foundation of meticulous, multi-faceted research. This multi-pronged approach underscores a long-term commitment to not only treating symptoms but fundamentally altering the course of these devastating brain diseases.